Clinical Trials
63 trialsTAURUS
European Myeloma Network B.V.
Bendamustine + Pomalidomide + Dex in R/R Multiple Myeloma
Duke University
SPODUMENE
Peking University People's Hospital
ATG-010(Selinexor) in Combination With Chemotherapy in RRMM
Union Hospital, Tongji Medical College, Huazhong University of Science and Technology
A Study to Investigate the Safety and Clinical Activity of Belantamab Mafodotin in Combination With Daratumumab, Lenalidomide and Dexamethasone in Patients With Newly Diagnosed Multiple Myeloma Transplant Ineligible
Hellenic Society of Hematology
APG-2575 in Combination With Novel Therapeutic Regimens in Subjects With Relapsed or Refractory Multiple Myeloma
Ascentage Pharma Group Inc.
CURATE.AI Optimized Modulation for Multiple Myeloma
National University Hospital, Singapore
Daratumumab in Combination With Bortezomib and Dexamethasone in Newly Diagnosed Transplant Ineligible Multiple Myeloma
Singapore General Hospital
LENDER
Kosin University Gospel Hospital
The Efficacy and Safety of Colchicine Combined With Conventional Therapy in Multiple Myeloma Patients
Affiliated Hospital of Nantong University
Selinexor in Combination With Immunomodulator ļ¼Thalidomide/Pomalidomide/Lenalidomideļ¼in RRMM
Shanghai Changzheng Hospital
PVd Versus Vd in NDMM Patients With RI
RenJi Hospital
Multicenter Open Label Phase 2 Study of Isatuximab Plus Pomalidomide and Dexamethasone With Carfilzomib in Relapsed or Refractory Multiple Myeloma
Poitiers University Hospital
Anlotinib Hydrochloride Capsule Monotherapy and Combination Therapy Relapsed and Refractory Multiple Myeloma
Institute of Hematology & Blood Diseases Hospital, China
KMM1910
Samsung Medical Center
Carfilzomib, Cyclophosphamide, Dexamethasone in Multiple Myeloma
PETHEMA Foundation
KMM2002
Samsung Medical Center
Long-term KRd in Relapsed and/or Refractory Multiple Myeloma
Dong-A University Hospital
A Phase 2 Study of Isatuximab in Combination With Bortezomib, Cyclophosphamide and Dexamethasone Followed by Isatuximab and Lenalidomide Maintenance in Newly Diagnosed Patients With Multiple Myeloma and Severe Renal Impairment
Hellenic Society of Hematology
A Phase 2 Study of Isatuximab in Combination With Pomalidomide and Dexamethasone in MM Patients Who Received One Prior Line of Therapy Containing Lenalidomide and a Proteasome Inhibitor
Hellenic Society of Hematology
A Study of the Efficacy and Safety of Pomalidomide Capsules Combined With Low-Dose Dexamethasone in Subjects With Relapsed and Refractory Multiple Myeloma
Qilu Pharmaceutical Co., Ltd.
GEM-CLARIDEX
PETHEMA Foundation
Mitoxantrone Hydrochloride Liposome Injection, Bortezomib and Dexamethasone in the Treatment of R/R MM
CSPC Zhongnuo Pharmaceutical (Shijiazhuang) Co., Ltd.
Dose Escalation and Expansion Study of CM313 in Subjects With Relapsed or Refractory Multiple Myeloma and Lymphoma
Keymed Biosciences Co.Ltd
Study of BiRd Regimen Combined With BCMA CAR T-cell Therapy in Newly Diagnosed Multiple Myeloma (MM) Patients
The First Affiliated Hospital of Soochow University
Observation of the Efficacy of BAd Regimen in the Treatment of Relapsed and Refractory Multiple Myeloma
Shengjing Hospital
FiTNEss
University of Leeds
Selinexor in Combination With Thalidomide and Dexamethasone in RRMM
Sichuan University
The Efficacy and Safety of Pomalidomide and Bendamustine With Dexamethasone in Relapsed or Refractory Multiple Myeloma
Sun Yat-sen University
IFM2018-01
University Hospital, Toulouse
PDD vs PAD to Treat Initially Diagnosed MM
The First Affiliated Hospital of Soochow University
a Clinical Trial of Efficacy and Safety of the Holistic Treatment of Young High-risk Multiple Myeloma Patients
Institute of Hematology & Blood Diseases Hospital, China
DARIA
Hellenic Society of Hematology
MM-POM-2018
Instituto de Seguridad y Servicios Sociales de los Trabajadores del Estado
Phase 2 Trial of Chidamide-Lenalidomide-Dexamethasone(CRD) Regimen in R/R MM
Shanghai Zhongshan Hospital
Myeloma XI
University of Leeds
Efficacy and Toxicity Study of Pomalidomide and Dexamethasone in Patients Who Have Relapsed After Exposure to Lenalidomide and Bortezomib
National University Hospital, Singapore
Modified Bortezomib-based Combination Therapy for Multiple Myeloma
Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine
CyBorD-Dara
National University of Ireland, Galway, Ireland
Safety, Efficacy, and Pharmacodynamics of a 60-Minute Infusion of Carfilzomib for Progressive Multiple Myeloma
Oncotherapeutics
CTd
Jinling Hospital, China
Tolerability and Efficacy of Modified VCD Regimens in Previously Untreated Multiple Myeloma.
Jinling Hospital, China
METDEXA-MM
University of Campinas, Brazil
Efficacy and Safety of Pomalidomide in Combination With Low-dose Dexamethasone in Chinese Patients With Relapsed and Refractory Multiple Myeloma
Jiangsu Simcere Pharmaceutical Co., Ltd.
Open-label Study of TH-302 and Dexamethasone With or Without Bortezomib or Pomalidomide in Subjects With Relapsed/Refractory Multiple Myeloma
Threshold Pharmaceuticals
CyBorD vs. PAD in the Treatment of Newly Diagnosed Multiple Myeloma
Sun Yat-sen University
Pomalidomide, Dexamethasone and Pegylated Liposomal Doxorubicin for Relapsed/Refractory Multiple Myeloma
Oncotherapeutics
Phase-0-MM
Aalborg University Hospital
MUKsix
University of Leeds
Efficacy of Monosialotetrahexosylganglioside in the Prophylactic Treatment of Bortezomib-induced Peripheral Neuropathy
Sun Yat-sen University